MW EG169 articl NS 20160223171404 captis executive search management consulting leadership board services

IGM Biosciences price target raised to $119 from $86 at Truist Securities, stock rated buy

MW EG169 articl NS 20160223171404 captis executive search management consulting leadership board services

IGM Biosciences Inc.

IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firms product pipe line includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin’s lymphoma and other B cell malignancies; IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies; and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.

This is not a CAPTIS article. Originally, it was published here.